ALDH2 and Hyperglycemia: In our earlier study, we decreased cardiac 4HNE adduct levels in ALDH2*2 diabetic mice by decreasing hyperglycemia via empagliflozin (EMP), a sodium-glucose cotransporter (SGLT) 2 inhibitor, and thereby improved cardiac function via altering metabolic signaling [15].